Kamat Pharmatech
Kamat Pharmatech is a US-based pharmaceutical contract development organization specializing in formulation development, regulatory strategy, and the advancement of complex generics, injectable, lyophilized, oral liquid, and topical drug products. With over a decade of experience and scientific leadership in lyophilization, injectables, topicals, and regulatory pathways, the company serves as a partner for pharmaceutical firms seeking expertise in development, characterization, and US-FDA compliance.
Industries
Nr. of Employees
small (1-50)
Kamat Pharmatech
685 US Highway 1, North Brunswick, NJ 08902
Products
Nystatin oral suspension (launched)
Oral suspension formulation of nystatin that the company reports launched with market uptake in the US.
Trazodone oral solution (505(b)(2) product launched)
A trazodone oral solution launched via a 505(b)(2) pathway reported by the company.
Nystatin oral suspension (launched)
Oral suspension formulation of nystatin that the company reports launched with market uptake in the US.
Trazodone oral solution (505(b)(2) product launched)
A trazodone oral solution launched via a 505(b)(2) pathway reported by the company.
Expertise Areas
- Complex injectable development
- Lyophilization and freeze-drying
- Formulation development (oral liquids, topicals, ophthalmics)
- Aseptic and sterile processing
Key Technologies
- Lyophilization (freeze-drying)
- Nano-suspension technology
- Aseptic processing
- Liposome and emulsion formulation
Key People
News & Updates
Successful product launch resulting in significant US market share for this oral suspension.
Successful development and commercialization of a 505(b)(2) regulatory pathway oral solution product in the United States.
Preparing regulatory filings and launching five new unique pharmaceutical products within the next 1–2 years.
Successful product launch resulting in significant US market share for this oral suspension.
Successful development and commercialization of a 505(b)(2) regulatory pathway oral solution product in the United States.
Preparing regulatory filings and launching five new unique pharmaceutical products within the next 1–2 years.